Welcome to our dedicated page for AAPGV news (Ticker: AAPGV), a resource for investors and traders seeking the latest updates and insights on AAPGV stock.
This page aggregates news related to AAPGV and Ascentage Pharma, a global, integrated biopharmaceutical company whose American depositary shares trade on the Nasdaq Global Market under the ticker symbol AAPG. Ascentage Pharma describes its business as discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies.
News about AAPGV, through its link to Ascentage Pharma, often centers on capital markets activity and disclosures tied to the company’s listings in Hong Kong and the United States. Recent announcements have included the closing of a U.S. initial public offering of American depositary shares on Nasdaq and a partial exercise of the underwriters’ option to purchase additional ADSs. These items highlight how the company raises capital and structures its equity through ADSs that represent its ordinary shares.
Investors following this news stream can review updates on the number of ADSs offered, the exercise of over-allotment options, and other information the company releases in connection with its public offerings and listings. Because Ascentage Pharma emphasizes its focus on hematological malignancies and global unmet medical needs, company communications may also reference how capital raised supports its biopharmaceutical activities.
Use this page as a central source for company-issued announcements and market-facing updates related to AAPGV and Ascentage Pharma’s Nasdaq-listed ADSs. For a full understanding of any transaction or disclosure, readers should consult the original news releases and official company documents referenced in these items.
Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced that underwriters of its U.S. initial public offering have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (ADSs) at $17.25 per ADS. Each ADS represents four ordinary shares of the company.
Following this partial exercise, the total number of ADSs sold in the offering will increase to 8,260,144, bringing the aggregate gross proceeds to approximately $142.5 million, before deducting underwriting discounts, commissions, and other offering expenses. J.P. Morgan and Citigroup served as joint book-running managers for the offering.
Ascentage Pharma (Nasdaq: AAPG) has successfully completed its U.S. initial public offering, raising approximately $126.4 million in gross proceeds. The company offered 7,325,000 American depositary shares (ADSs) at $17.25 per ADS, with each ADS representing four ordinary shares. Trading of the ADSs commenced on the Nasdaq Global Market on January 24, 2025.
The company has granted underwriters a 30-day option to purchase up to an additional 1,098,750 ADSs at the initial offering price, less underwriting discounts and commissions. J.P. Morgan and Citigroup served as joint book-running managers for the offering.